Prinaberel

Prinaberel (ERB-041) is a potent and selective estrogen receptor (ER) β agonist with IC50s of 5.4, 3.1 and 3.7 nM for human, rat and mouse ERβ, respectively. Prinaberel displays >200-fold selectivity for ERβ over ERα. Prinaberel is a potent skin cancer chemopreventive agent that acts by dampening the WNT/β-catenin signaling pathway. Prinaberel induces ovarian cancer apoptosis[1][2][3].

Product Specifications

CAS Number

[524684-52-4]

Product Name Alternative

ERB-041

UNSPSC

12352005

Hazard Statement

H302, H319

Target

Apoptosis; Estrogen Receptor/ERR; Wnt

Type

Reference compound

Related Pathways

Apoptosis; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Prinaberel.html

Purity

98.05

Solubility

DMSO : ≥ 40 mg/mL

Smiles

OC1=CC(C=C)=C(OC(C2=CC=C(O)C(F)=C2)=N3)C3=C1

Molecular Formula

C15H10FNO3

Molecular Weight

271.24

Precautions

H302, H319

References & Citations

[1]Malamas MS, et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004;47 (21) :5021-5040.|[2]Chaudhary SC, et al. Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila) . 2014;7 (2) :186-198.|[3]Chan KKL, et al. Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer. Cancer Cell Int. 2018;18:65. Published 2018 May 1.